Fundraising Fox

Checkpoint Therapeutics

Waltham, US · Founded 2014 · Delaware corporation

Biotech

Founders & leadership

JF
James F. Oliviero, IIIExecutive
GG
Garrett GrayExecutive
DJ
David J. HorinExecutive
MS
Michael S. WeissNamed on SEC filing

Board

MW
Michael WeissBoard director
LA
Lindsay A. RosenwaldBoard director
BS
Barry SalzmanBoard director
AS
Amit SharmaBoard director
NH
Neil HerskowitzBoard director
CB
Christian BechonBoard director
SB
Scott BoilenBoard director

Reported raises · per SEC filings

Form D private placements

$57.8M disclosed across 1 of 5 rounds · 2015–2024

▶Undisclosed amountofferedJul 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barry SalzmanDirector
  • Michael WeissDirector
  • Amit SharmaDirector
  • Neil HerskowitzDirector
  • Christian BechonDirector
  • Lindsay A. RosenwaldDirector
  • James F. Oliviero, IIIExecutive Officer, Director
  • Garrett GrayExecutive Officer
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Garrett GrayExecutive Officer
  • James F. Oliviero, IIIExecutive Officer, Director
  • Michael WeissDirector
  • Christian BechonDirector
  • Lindsay A. RosenwaldDirector
  • Barry SalzmanDirector
  • Neil HerskowitzDirector
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedApr 2023 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christian BechonDirector
  • Lindsay A. RosenwaldDirector
  • Garrett GrayExecutive Officer
  • Neil HerskowitzDirector
  • Michael WeissDirector
  • Barry SalzmanDirector
  • James F. Oliviero, IIIExecutive Officer, Director
  • Scott BoilenDirector
Placement agents
H.C. Wainwright & Co., LLC
First sale
Mar 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedMar 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James F. Oliviero, IIIExecutive Officer, Director
  • Garrett GrayExecutive Officer
  • Michael WeissDirector
  • Neil HerskowitzDirector
  • Scott BoilenDirector
  • Barry SalzmanDirector
  • Christian BechonDirector
  • Lindsay A. RosenwaldDirector
Placement agents
H.C. Wainwright & Co.
First sale
Feb 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$57.8MraisedSep 2016 · 559 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lindsay A. RosenwaldDirector
  • David J. HorinExecutive Officer
  • Michael S. WeissDirector
  • James F. Oliviero, IIIExecutive Officer
  • Neil HerskowitzDirector
  • Scott BoilenDirector
  • Barry SalzmanDirector
Offering amount
$62.5M
Amount sold
$57.8M
Sales commissions
$5.8M
Placement agents
National Securities Corporation
First sale
Sep 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Checkpoint Therapeutics finalizes acquisition by Sun Pharma By Investing.cominvesting.com · May 2025Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock Newsstocktitan.net · Nov 2024

Frequently asked questions

How much funding has Checkpoint Therapeutics raised?
Checkpoint Therapeutics has disclosed $57.8M raised across 1 of its 5 known rounds.
Where is Checkpoint Therapeutics headquartered?
Checkpoint Therapeutics is headquartered in Waltham, US.